新闻
MNKD
--
0.00%
--
从昨天开始的 61 个最大的推动者
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
Benzinga · 06/29 08:58
44 只股票在周一的午盘交易中移动
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.
Benzinga · 06/28 16:03
Cramer 对 Carlotz、MannKind 等发表了自己的看法
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is staying away from Carlotz Inc (NASDAQ: LOTZ). He is done with the used cars for now.
Benzinga · 06/28 11:50
政策变更允许从 7 月 18 日开始批准患有糖尿病的 Medicare 患者使用 Afrezza® 和连续血糖监测设备
MannKind Corporation (NASDAQ:MNKD) appreciates the recent efforts of the Centers for Medicare and Medicaid Services (CMS) in conjunction with the Medicare Administration Contractors (MACs) to implement a policy
Benzinga · 06/28 10:16
克莱默的闪电回合:MannKind 是为了投机
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 06/25 23:40
MannKind 在美国糖尿病协会第 81 届虚拟科学会议上展示两张海报,6 月 25 日至 29 日
MannKind Corporation (NASDAQ:MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's
Benzinga · 06/25 15:35
MannKind 计划在秋季对儿科患者进行晚期 Afrezza 胰岛素粉试验
MT Newswires · 06/25 15:09
靠一款干粉吸入器,分析师为何看好药企MNKD还能再涨40%?
华盛资讯 · 06/22 07:49
奥本海默对 Mannkind 在 Tyvaso DPI 申请 FDA 批准方面的持续进展感到鼓舞
MT Newswires · 06/18 16:00
在对 Tyvaso DPI NDA 进行优先审查后,MannKind 股价上涨 9%
marketwatch.com · 06/16 14:48
12 只医疗保健股在周三的盘前交易时段内移动
 
Benzinga · 06/16 12:07
MannKind - United Therapeutics 的曲前列环素正在接受 FDA 的肺动脉高压审查
Benzinga · 06/16 11:26
Brief-United Therapeutics 宣布 FDA 接受 Tyvaso Dpi™ 新药申请进行优先审查
reuters.com · 06/16 10:26
The Daily Biotech Pulse:美国将采购 500M 辉瑞-BioNTech 疫苗剂量用于捐赠,维罗纳批准 COPD 药物,鹦鹉螺通过 SPAC 交易上市
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9)
Benzinga · 06/10 12:13
MannKind 和 Thirona 研究皮肤纤维化的治疗方法
marketwatch.com · 06/10 10:56
MannKind 与 Thirona Bio 合作开发治疗纤维化肺病的潜在疗法
MT Newswires · 06/10 06:55
昨天的 68 个最大的推动者
Gainers
Benzinga · 06/02 09:00
ROCE对MannKind的见解
MannKind (NASDAQ:MNKD) reported Q1 sales of $17.44 million. Earnings fell to a loss of $10.03 million, resulting in a 49.19% decrease from last quarter. MannKind collected $18.44 million in revenue during Q4, but reported earnings showed a $19.74 million l...
Benzinga · 05/26 12:57
Brief-Mannkind Corp-5月24日,公司与Amphastar Pharmaceuticals,Inc.签署了第六项修正案以提供供应协议。
reuters.com · 05/25 10:15
Benzinga的最高评级升级,2021年5月14日降级
 
Benzinga · 05/14 14:03
微牛提供丰富的实时MNKD股票新闻,让你可以通过多个平台了解MNKD股票行情最新动态,这些免费的曼恩凯德生物医疗新闻可以帮助你做出明智投资。
MNKD 简况
MannKind Corp是一家生物制药公司。该公司专注于糖尿病和孤儿肺疾病(如肺动脉高压)的吸入治疗产品的开发和商业化。该公司的主导产品是Afrezza Inhalation Powder,这是一种吸入胰岛素,用于改善成人糖尿病患者的血糖控制状况。Afrezza由一种从小型便携式吸入器输送的人胰岛素干粉制剂组成。AFREZZA利用其技术圈配方技术。技术圈是一个药物输送平台,可以允许口服吸入多种治疗药物。